Clinical efficacy and safety of fixed intranasal combination of fluticasone propionate and azelastine hydrochloride for the treatment of seasonal allergic rhinitis

Allergic rhinitis (AR) is a common chronic respiratory disease that affects millions of people worldwide and has a significant impact on their quality of life, productivity, and performance. Achieving control of symptoms of moderate/severe AR, which often requires the use of several drugs from different pharmacological groups, is particularly challenging intranasal fixed combination (InFC) of fluticasone propionate (FP) and azelastine hydrochloride (AZE) (MP-AzeFlu) for the treatment of seasonal AR (SAR). The combination of FP and AZE demonstrates a synergistic effect in improving the symptoms of both early and late allergic reactions, and has a pronounced anti-inflammatory effect. Studies show that the use of MP-AzeFlu leads to a significant improvement in the nasal and ocular symptoms of SAR compared to FP and AZE monotherapy. The drug provides a rapid onset of action and sustained relief of symptoms, which contributes to an improved quality of life for patients. The article provides an overview of the main studies devoted to preclinical, clinical randomized trials and studies in real clinical practice on the efficacy and safety of the fixed intranasal combination, including in comparison with monodrugs included in its composition and placebo. It demonstrates its effectiveness in different populations regardless of race, gender and age, including long-term use. FP in combination with AZE has the most extensive evidence base of studies, including those conducted on the Russian patient population. The drug can be used in patients since 12 years with moderate to severe seasonal AR. It is included in all international and Russian recommendations on AR.